CARISMA THERAPEUTICS INC by Carisma Therapeutics, Inc. Financials - Benzinga

CARISMA THERAPEUTICS INC by Carisma Therapeutics, Inc.

CARMOTCEM

Trade with Public

Trade with Public

$0.1539

At close: Oct 20, 5:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare

CARISMA THERAPEUTICS INC by Carisma Therapeutics, Inc. Financials

CARISMA THERAPEUTICS INC by Carisma Therapeutics, Inc. (CARM) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
CARISMA Therapeutics Q3 EPS $1.07 Beats $(0.12) Estimate, Sales $45.250M Beat $3.771M Estimate

CARISMA Therapeutics (NASDAQ:CARM) reported quarterly earnings of $1.07 per share which beat the analyst consensus estimate of $(0.12) by 991.67 percent. This is a 445.16 percent increase over losses of $(0.31) per share

Benzinga Newsdesk

Nasdaq Down 1%; Signet Jewelers Earnings Top Views

Avi Kapoor

Dow Rises Over 50 Points; US Inflation Rate Increases In May

Avi Kapoor

PRO
CARISMA Therapeutics Q1 EPS $(0.22) Misses $(0.10) Estimate, Sales $3.73M Inline

CARISMA Therapeutics (NASDAQ:CARM) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.10) by 120 percent. This is a 52.17 percent increase over losses of $(0.46) per share

Benzinga Newsdesk

PRO
CARISMA Therapeutics' Q3 Cash And Cash Equivalents Of $26.9M Expected To Fund The Company Into The Third Quarter Of 2025

Benzinga Newsdesk

PRO
CARISMA Therapeutics Q3 2024 GAAP EPS $(0.31) Misses $(0.24) Estimate, Sales $3.38M Miss $5.47M Estimate

CARISMA Therapeutics (NASDAQ:CARM) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.24) by 29.17 percent. The company reported quarterly sales of $3.38 million which

Benzinga Newsdesk